Treats serious bacterial infections caused by susceptible strains of the designated…. ANDA 206965, held by Baxter Hlthcare Corp. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 206965 (Tobramycin Sulfate), held by Baxter Hlthcare Corp, was first approved by FDA on Jul 1, 2016, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp. Lower respiratory tract infections caused by P. aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tobramycin SulfateEQ 40MG BASE/ML · injectable;injection | Tobramycin Sulfate | Discontinued |
| Feb 10, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 17, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 17, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 1, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters